Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).

Inclusion Criteria

1. Written informed consent and HIPAA authorization for release of personal health

information.

2. Age ≥ 18years at the time of consent.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 28 days

prior to registration.

4. Radiographically consistent with metastatic renal cell carcinoma (with subsequent

pathologic confirmation of renal cell carcinoma with a clear cell component) OR

histological/ cytological evidence of metastatic renal cell carcinoma with a clear

cell component

5. Measurable tumor in the kidney according to RECIST 1.1

6. No prior therapy for metastatic renal cell carcinoma

7. Demonstrate adequate organ function as defined in the protocol; all screening labs to

be obtained within 14 days prior to registration.

8. Females of childbearing potential must have a negative serum pregnancy test during

screening, within 14 days of Cycle 1 Day 1. NOTE: Females are considered of child

bearing potential unless they are surgically sterile (have undergone a hysterectomy,

bilateral tubal ligation, or bilateral oophorectomy) or they are naturally

postmenopausal for at least 12 consecutive months

9. Females of childbearing potential and males must be willing to abstain from

heterosexual activity or to use 2 forms of effective methods of contraception from the

time of informed consent until 6 months after treatment discontinuation. The two

contraception methods can be comprised of two barrier methods, or a barrier method

plus a hormonal method.

10. As determined by the enrolling physician or protocol designee, ability of the subject

to understand and comply with study procedures for the entire length of the study

Exclusion Criteria

1. Patients who had previously undergone nephrectomy for renal cancer are excluded

2. Uncontrolled bleeding, hypertension, or cardiovascular disease.

3. Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4 inhibitors

4. The subject has active brain metastases or epidural disease

5. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy

within 4 weeks before first dose of study treatment.

6. The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial

thromboplastin time (PTT) test ≥1.3 x the laboratory upper limit of normal (ULN)

7. The subject requires concomitant treatment, in therapeutic doses, with anticoagulants

such as warfarin or warfarin-related agents, thrombin or Factor Xa inhibitors. Aspirin

(up to 325 mg/day), low-dose warfarin (≤1 mg/day), prophylactic and therapeutic low

molecular weight heparin (LMWH) are permitted

8. Clinically-significant gastrointestinal bleeding within 6 months before the first dose

of study treatment

9. Hemoptysis of ≥0.5 teaspoon (2.5 mL) of red blood within 3 months before the first

dose of study treatment

10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease

manifestation.

11. The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or

large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor

within 28 days before the first dose of cabozantinib

12. Patients with active autoimmune disease or history of autoimmune disease that might

recur, which may affect vital organ function or require immune suppressive treatment

13. Patients are excluded if they have a condition requiring systemic treatment with

either corticosteroids (>10 mg daily prednisone equivalents) or other

immunosuppressive medications within 14 days of study start

14. Cardiovascular disorders including:

- Congestive heart failure (CHF): New York Heart Association (NYHA) Class III

(moderate) or Class IV (severe) at the time of screening

- Concurrent uncontrolled hypertension defined as sustained BP > 150 mm Hg

systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment

within 14 days of the first dose of study treatment.

- The subject has a corrected QT interval calculated by the Fridericia formula

(QTcF) >500 ms within 28 days before registration.

15. Severe active infection requiring systemic treatment within 28 days before the first

dose of study treatment

16. Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of

study treatment

17. Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks

before first dose of study treatment. Complete wound healing from major surgery must

have occurred 1 month before first dose and from minor surgery (e.g., simple excision,

tooth extraction) at least 10 days before first dose. Subjects with clinically

relevant ongoing complications from prior surgery are not eligible.

18. History of organ transplant

19. Concurrent uncompensated hypothyroidism

20. Unable to swallow tablets

21. Active infection requiring systemic therapy

22. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the

mother is being treated on study).

23. Known additional malignancy that is active and/or progressive requiring treatment;

exceptions include basal cell or squamous cell skin cancer, in situ cervical or

bladder cancer, or other cancer for which the subject has been disease-free for at

least 2 years.

24. Active central nervous system (CNS) metastases

25. Treatment with any investigational drug within 28 days prior to registration.